Mosaic HIV Envelope Polypeptides for Broad Strain Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV vaccines face challenges due to viral diversity and the emergence of escape variants, making it difficult to develop effective vaccines that can elicit broad and durable immune responses against human immunodeficiency virus (HIV).
Innovation Solution
Development of mosaic HIV envelope (Env) proteins that are computationally designed to optimize coverage of global HIV diversity, eliciting immune responses through the use of sets of immunogenic polypeptides or nucleic acids encoding these proteins, which can induce cytotoxic T cell, helper T cell, and humoral responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional HIV vaccines are used, then vaccine development progresses, but viral diversity and escape variants reduce effectiveness
Solution Approach 1:
The HIV envelope protein is divided into multiple regions (V1, V2, V3, V4 variable regions and C1, C2 constant regions) that are recombined to create mosaic proteins. This segmentation allows the vaccine to present multiple epitope variants simultaneously, addressing viral diversity by targeting conserved regions while accommodating strain variation through modular region combination.
Solution Approach 2:
The mosaic Env proteins are designed to serve multiple functions: they maintain structural integrity of the envelope protein while incorporating diverse epitope sequences from multiple HIV strains. This multi-functionality enables a single vaccine candidate to target both conserved and variable regions across different HIV clades, improving universal coverage.
2Adaptability or versatility
If mosaic Env proteins are designed to cover global HIV diversity, then coverage of common epitope variants increases, but protein structural complexity increases
Solution Approach 1:
Different regions of the mosaic Env protein are assigned specific functions: variable regions (V1-V4) are designed to present diverse epitopes for recognizing different HIV strains, while constant regions (C1-C2) are optimized to maintain stable protein folding and structural integrity. This local differentiation allows the protein to achieve broad coverage without compromising overall structural stability.
Solution Approach 2:
The mosaic Env protein functions as a composite structure combining segments from different HIV strains and regions. By integrating variable and constant regions from multiple sources into a single chimeric protein, the vaccine achieves both structural stability and epitope diversity, resolving the conflict between complexity and coverage.
3Reliability
If type-specific responses are minimized, then broad neutralizing antibody responses are enhanced, but vaccine design complexity increases
Solution Approach 1:
The mosaic Env proteins introduce dynamic variability through their composite structure, presenting multiple epitope configurations that can adapt to different HIV strains. This dynamic presentation of diverse epitopes within a single vaccine formulation promotes the development of broadly neutralizing antibodies while minimizing type-specific responses, as the immune system encounters multiple variants simultaneously.
Data Source
AI summary
Disclosed herein are mosaic HIV envelope (Env) polypeptides that can elicit an immune response to HIV (such as cytotoxic T cell (CTL), helper T cell, and/or humoral responses). Also disclosed are sets of the disclosed mosaic Env polypeptides, which include two or more (for example, three) of the polypeptides. Also disclosed herein are methods for treating or inhibiting HIV in a subject including administering one or more of the disclosed immunogenic polypeptides or compositions to a subject infected with HIV or at risk of HIV infection. In some embodiments, the methods include inducing an immune response to HIV in a subject comprising administering to the subject at least one (such as two, three, or more) of the immunogenic polypeptides or at least one (such as two, three, or more) nucleic acids encoding at least one of the immunogenic polypeptides disclosed herein.